Table 2.
Baseline characteristics of all patients with COVID-19
| QT prolongation |
P | ||
|---|---|---|---|
| Characteristic | Present (n = 103) | Not present (n = 356) | |
| Age (y) | 68.2 ± 15.2 | 64.8 ± 17.5 | .137 |
| Male sex | 64 (62.1) | 197 (55.3) | .220 |
| Severity of disease | |||
| ICU during hospitalization | 60 (58.3) | 130 (36.5) | .000 |
| Intubation required during hospitalization | 32 (31.1) | 70 (19.7) | .014 |
| COVID-19–related medications | |||
| Hydroxychloroquine | 98 (95.1) | 317 (89.0) | .064 |
| Tocilizumab | 83 (80.6) | 223 (62.6) | .001 |
| Hydroxychloroquine + atazanavir | 21 (20.4) | 47 (13.2) | .071 |
| Other COVID-19–related medications | 7 (6.8) | 19 (5.3) | .573 |
Values are presented as mean ± SD or as n (%).
Other COVID-19–related medications include remdesivir, nivolumab, ritonavir/lopinavir, ruxolitinib, sarilumab, and plasma.
COVID-19 = coronavirus disease 2019; ICU = intensive care unit.